Fight Cancer With Our Breakthrough Drug Prediction Platform – DxPP
Fight Cancer With Our Breakthrough Drug Prediction Platform – DxPP
Discover the difference our first-in-kind AI and therapy resistant cell technologies bring to treatment planning and drug development for cancer patients.
Discover the difference our first-in-kind AI and therapy resistant cell technologies bring to treatment planning and drug development for cancer patients.
First Ascent’s Ex Vivo Drug Response Identification & Validation Engine – xDRIVE Platform is a first-in-kind medical oncology decision support system that integrates functional drug testing, DNA/RNA sequencing and AI-guided tumor weakness mapping resulting in prioritized therapeutic solutions tailored to the patient’s tumor vulnerabilities and validated through tests run on the patient’s own cells.
Publication and Pharma Partners
The Latest First Ascent Biomedical News
Inside Precision Medicine April 18, 2024 IPM interviewed Dr. Diana Azzam First Ascent co-founder and [...]
Groundbreaking findings published in Nature Medicine shows improved outcomes when standard treatments fail Miami, [...]
Function Precision Medicine (FPM) and AI to provide new treatment options for minority childhood cancer [...]